GLP-1 Muscle Preservation: What the STAY-LEAN Trial Tests

Every patient who starts a GLP-1 asks the same question before the first injection: how much of the weight I lose will be muscle?

It is a legitimate question, and until recently the honest answer has been "we don't fully know." That is changing. A randomized trial now running at the Cleveland Clinic is testing exactly this problem, and a new narrative review has pulled together the first real body-composition data on tirzepatide.

Here is what the evidence actually shows — and what to do with it.

What the STAY-LEAN trial is actually testing

Most GLP-1 trials measure one thing: how much weight you lose. The STAY-LEAN trial — formally, Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance (NCT06854614) — is designed around a different question: can you keep weight off long-term without sacrificing lean mass?

Key facts about the design:

• 150 participants, randomized, open-label, single-center at the Cleveland Clinic
• Phase 1 (9 months): everyone receives tirzepatide 15 mg (or semaglutide 2.4 mg if tirzepatide isn't tolerated), plus a structured lifestyle program
• Phase 2 (12 months): participants are re-randomized either to continue tirzepatide or semaglutide, or switch to a different anti-obesity medication (phentermine-topiramate or naltrexone-bupropion)
• The primary endpoint is sustained weight loss at month 21 — but the secondary and exploratory endpoints are where it gets interesting: percentage of fat mass lost, lean muscle mass, functional capacity, muscle strength, and compliance with lifestyle changes

In other words, STAY-LEAN doesn't just ask whether the weight stays off. It asks what kind of weight you keep — and whether you're still functionally strong at the end of it.

That framing matters. Losing 20% of your weight and regaining it as fat is a different outcome than losing 20% and maintaining your lean mass. The trial is built to tell the difference.

What the tirzepatide lean-mass data shows so far

A 2026 narrative review published in Current Medical Research & Opinion (Wilkinson and Ramzan) examined ten studies — randomized controlled trials, observational studies, and modeling analyses — to answer one question: what happens to lean mass when you lose weight on tirzepatide?

The findings:

• Weight loss is consistently large and dose-dependent — no surprise there
• Fat mass accounts for most of the loss, but lean mass, fat-free mass, or skeletal muscle mass decreased in every study included
• The proportion of total weight loss attributable to lean mass ranged from roughly 10% to 30% — which the authors note broadly aligns with what you'd expect from any form of weight loss, not something unique to GLP-1s
• The measurement problem is real: most studies used bioelectrical impedance rather than DEXA scans, and none assessed functional outcomes — meaning we don't yet know whether the observed lean-mass reductions translate into weakness or frailty
• The clinical significance remains uncertain

The review's bottom line: tirzepatide appears to promote preferential fat loss, some lean-mass loss occurs (as it does with any weight-loss intervention), and resistance training plus adequate protein intake may help mitigate it.

That is a more measured picture than the marketing on either side. You are not going to waste away on tirzepatide. You are also not going to preserve every ounce of muscle without doing anything about it.

Why "some muscle loss" doesn't mean "get weaker"

A critical distinction the review draws: losing lean mass on a scale is not the same as losing functional strength.

When you lose weight — by any method — you shed water, glycogen, fat, and some lean tissue. Some of that lean-tissue loss is simply the muscle your body no longer needs to carry around a smaller frame. A 280-pound person doesn't need the same lower-body musculature as a 220-pound person.

What matters clinically is whether the remaining muscle is sufficient for daily function, balance, and metabolic health. That is why STAY-LEAN's inclusion of functional capacity and strength endpoints is significant — it's measuring what patients actually care about, not just what a scale says.

The protocol stack: resistance training + protein

The review and the STAY-LEAN trial converge on the same practical strategy. If you want to protect your muscle on a GLP-1, the intervention isn't complicated.

1. Resistance training 2–3x per week

This is the single highest-leverage intervention. Resistance training sends a signal to your body that the muscle is still needed — which shifts the composition of what you lose toward fat. You don't need a complicated program. Full-body movements (squat, hinge, push, pull) performed consistently, with progressive load, are sufficient.

2. Protein intake aligned to your goal weight

Adequate protein supports muscle protein synthesis even in a calorie deficit. General clinical guidance for patients on GLP-1s undergoing weight loss points toward roughly 1.2–1.6 grams per kilogram of body weight — but your prescriber or a registered dietitian should set your target based on your health profile, kidney function, and medication plan.

For a deeper look at how protein intake interacts with GLP-1-driven body composition, see our guide on protein and muscle on GLP-1 body composition. If you're earlier in the process and want the full nutrition picture — including micronutrient considerations — our GLP-1 nutrition and muscle preservation guide covers the dietary foundation.

3. Creatine: plausible, but talk to your clinician

A 2026 perspective published in Clinical Nutrition (Ostojic and Galyean) proposed creatine supplementation as a biologically plausible adjunct for muscle preservation during GLP-1-based weight loss. Their hypothesis: rapid weight loss, reduced energy and protein intake, and decreased mechanical loading create conditions of skeletal-muscle bioenergetic vulnerability — and creatine could support muscle energetics in that setting.

Important context: this is explicitly hypothesis-generating. No randomized clinical trial has tested creatine supplementation during GLP-1-based weight loss. If you're considering it, discuss it with your prescriber first — it's not appropriate for everyone, and your clinical team should know everything you're taking.

How this differs from just "eating better on a GLP-1"

The nutrition guides linked above focus on what to eat. This piece is about what the clinical evidence says about muscle loss itself — and what a formal protocol for preventing it looks like.

The distinction matters because most patients don't need another diet article. They need to know: is the fear of muscle loss a reason not to start a GLP-1? The answer, based on current evidence, is no — provided you train and eat for the outcome you want.

If you're still weighing whether tirzepatide or semaglutide is the right fit for your situation, our semaglutide or tirzepatide decision guide walks through the practical differences. If you're earlier in the process and comparing options, our breakdown of the best GLP-1 for weight loss covers the landscape.

What this means for you

If you're starting or already on a GLP-1:

• The muscle-loss risk is real but manageable. Current data suggests 10–30% of the weight you lose may be lean mass — but that's within the expected range for any weight loss, and functional outcomes haven't been shown to suffer.
• Resistance training is not optional if muscle preservation matters to you. It is the single most evidence-backed intervention.
• Protein intake matters. Talk to your prescriber about a target appropriate for your body and health profile.
• The evidence is still evolving. STAY-LEAN and other trials will sharpen the picture. What we know today supports doing the basics well — not waiting for a perfect protocol.

At LuxeFit Wellness, our muscle-preservation program pairs GLP-1 therapy with structured resistance training, protein planning, and regular body-composition monitoring so you can see what you're actually losing — and keep what you want to keep. Schedule a consultation to learn more.

---